Drug Type Trispecific killer cell engager (TriKE) |
Synonyms- |
Target |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), Interleukin-15 receptors modulators(Interleukin-15 receptors modulators), TEM8 inhibitors(ANTXR cell adhesion molecule 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 26 Sep 2022 |